Table 4.
All-cause mortality in COVID-19 patients with CAPA compared with controls
| Country | Case definition | # of CAPA patients | Mortality in CAPA | Mortality in controls | References |
|---|---|---|---|---|---|
| France | EORTC/MSGERC (if immunocompromised) [7] and IAPA [5] | 9 | 44% | 39% (p = 0.99) | [15] |
| Francea | Modified IAPA [8, 9] and EORTC/MSGERC [7] | 21 | 71.4% | 36.8% (p < 0.01) | [35] |
| Italy | IAPA [5] | 30 | 44% (day 30) | 19% (day 30) (p = 0.002)b | [19] |
| AspICU [8] | 19 | 74% | 26% ( p < 0.001) | ||
| United Kingdom | 19 | 58% (day 77?) | 38% | [20] | |
| Netherlands | 2020 ECMM/ISHAM [10] | 19 | 63.6% | 23.1% ( p = 0.013) | [28] |
| USA | 2020 ECMM/ISHAM [10] | 20 | 50% | 41.5% | [29] |
aIncludes cohort of Alanio et al. [15]
bDiagnosis of CAPA was associated with 30-day mortality from ICU admission (OR 3.53; 95% CI 1.29–9.67; p = 0.014), even after adjustment for age (OR 0.99; 95% CI 0.94–1.06; p = 0.99), need for renal replacement therapy (OR 3.02; 95% CI 1.11–8.19; p = 0.015), and SOFA score at ICU admission (OR 1.38; 95% CI 1.07–1.73; p = 0.004) with a logistic regression model [19]